By Doug Busch

Markets move in cycles, and leadership rarely disappears. It rotates, consolidates, and eventually reemerges.

Periods of volatility often create the most compelling opportunities to revisit prior ideas with fresh perspective. With several former selections now resetting after meaningful pullbacks, it is worth reassessing whether the technical foundations remain intact.

This week I focus on opportunities within communication services, healthcare, and consumer staples. Two of the names have endured meaningful drawdowns and now present compelling risk/reward profiles with clearly defined stops. In addition, I highlight an international food play that is immune from AI replication. Let's examine these three fresh ideas in detail below.

Netflix was covered by George Glover last December.

Boston Scientific was introduced by Jacob Sonenshine last October.

JBS NV was analyzed by Andrew Bary last August.

This is a weekly column. Read last week's edition here.

Netflix, a former communications services heavyweight, has come under intense pressure, tumbling 30% the last three months and now trades 43% below its most recent 52-week high. From 2022 through mid-2025, the stock was a clear leader on the ratio chart versus the State Street Communication Services Select Sector SPDR ETF. Since then, however, that leadership has eroded. The stock has fallen 33% since the author's recommendation.

On the monthly chart, the stock is on a five-month losing streak, its second longest stretch of declines in the past decade. The deterioration began subtly with a doji in September, though the earlier bearish engulfing candle in July should have had investors on defense following a staggering 737% advance from May 2022 through June 2025. Notably, that powerful run itself began with a bullish hammer followed by a bullish engulfing candle, underscoring how influential monthly candlesticks have been in marking major inflection points.

An entry on a pullback toward $75 appears constructive, aligning with the breakout above a cup base pivot at $70.20 from September 2024. A move toward $110 in the second half would represent 43% upside from current levels. Remain bullish above $69.

Netflix was trading around $77 Wednesday.

Boston Scientific, a medical device name, has come under notable pressure, down 20% year to date. Already in 2026, it has endured two sharp weekly declines of 9.8% and 18.5%, the latter occurring just two weeks ago on the heaviest weekly volume in at least five years. The stock now sits 30% below its most recent 52 week high, a drawdown three times deeper than that of the iShares U.S. Medical Devices ETF. The stock has fallen 24% since the author's recommendation.

A look at the weekly chart shows the breakdown below a bull flag at the start of the fourth quarter of 2025, a notable failure, as the adage reminds us that "nothing is more bearish than a bullish setup that fails." The 50 week simple moving average has now turned lower for the first time since the second half of 2022.

That said, last week's spinning top warrants attention, as such formations can signal potential exhaustion in the prevailing trend. Notably, the bears were unable to generate any follow-through after the prior week's sharp decline, despite the surge in volume. On a weekly basis, the relative strength index ( RSI) has reached its most oversold level in at least five years, suggesting downside momentum may be stretched. From current levels, a tactical entry here could target a move toward $91 by mid 2026, filling the Feb. 3 upside gap and representing 20% upside. Remain constructive above $72.

Boston Scientific was trading around $76 Wednesday.

JBS NV, a Dutch based food producer, is already off to a strong start in 2026, advancing 12% year to date. The stock is currently riding a five week winning streak and added nearly 1% on Tuesday to kick off the holiday shortened week. The stock has gained 12% since the author's recommendation.

Looking at the daily chart, the stock has spent nearly 10 months moving sideways on the ratio chart against the State Street Consumer Staples Select Sector SPDR ETF. Bulls would like to see a decisive relative breakout in the near term to confirm renewed leadership. Since the start of the year, price has consistently found support along its rising 21 day exponential moving average, reinforcing the short term uptrend.

Technically, the stock has carved out a cup with handle formation with a pivot at $16.44, with the base beginning with a bearish shooting star on August 27. Near the depth of the pattern, a bullish engulfing candle and a doji were recorded on Oct. 14 and Jan. 7 signaled exhaustion of selling pressure. A move above $16.44 would trigger the pattern, targeting $22 by mid-2026, approximately 38% upside from current levels. Remain bullish above $15.50.

JBS NV was trading around $16 Wednesday.

Sometimes the best new ideas are simply old winners ready for another run.

Doug Busch is the senior technical analyst at Barron's Investor Circle . His technical view is added to stock picks, including those published exclusively for Investor Circle readers. A glossary of technical terms is updated regularly with new entries.

This content was created by Barron's, which is operated by Dow Jones & Co. Barron's is published independently from Dow Jones Newswires and The Wall Street Journal.

(END) Dow Jones Newswires

February 18, 2026 10:47 ET (15:47 GMT)

Copyright (c) 2026 Dow Jones & Company, Inc.